stockrowEdgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
- EPS
- +2,846.5%
- Free cash flow
- −30.2%
Quarter to September 2026, against a year earlier
Follow EWTX
Alert me
Edgewise Therapeutics, Inc. (EWTX) Free cash flow
Edgewise Therapeutics, Inc.'s free cash flow for fiscal 2025 was −$144.1M, compared with −$110.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$202.3M. Over the past ten years it has ranged from −$144.1M (fiscal 2025) to −$14.8M (fiscal 2020) — the current reading is the lowest in ten years. Free cash flow has fallen for 5 consecutive fiscal years. Edgewise Therapeutics, Inc. ranks 510th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$144.1M | — |
| FY2024 | −$110.3M | — |
| FY2023 | −$97.7M | — |
| FY2022 | −$58.2M | — |
| FY2021 | −$34.2M | — |
| FY2020 | −$14.8M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$78.3M | — |
| Jun 2026 | −$42.5M | — |
| Mar 2026 | −$42.8M | — |
| Dec 2025 | −$38.7M | — |
| 23 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | $59.7M |
| ABCL AbCellera Biologics Inc. compare | −$119.7M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$121.8M |
| TNGX Tango Therapeutics, Inc. compare | −$144.2M |
| EWTX Edgewise Therapeutics, Inc. | −$158.8M |
| DFTX Definium Therapeutics, Inc. compare | −$168.0M |
| RLAY Relay Therapeutics, Inc. compare | −$212.2M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$216.1M |
| XENE Xenon Pharmaceuticals Inc. compare | −$338.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)